AstraZeneca and Merck announced that the FDA has accepted a supplemental New Drug Application (sNDA) for priority review for the approval of Lynparza tablets as a maintenance treatment in patients with newly-diagnosed, BRCA-mutated (BRCAm) advanced ovarian cancer who were in complete or partial response following first-line standard platinum-based chemotherapy. A Prescription Drug User Fee Act (PDUFA) date is…